Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial by Lean, Michael E.J. et al.
 
 
 
 
 
 
Lean, M. E.J. et al. (2019) Durability of a primary care-led weight-
management intervention for remission of type 2 diabetes: 2-year results of 
the DiRECT open-label, cluster-randomised trial. Lancet Diabetes and 
Endocrinology, 7(5), pp. 344-355. (doi:10.1016/S2213-8587(19)30068-3) 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it.  
 
 
http://eprints.gla.ac.uk/180894/  
 
 
 
 
 
 
   Deposited on: 28 February 2019 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of       
           Glasgow 
http://eprints.gla.ac.uk  
 
Draft 7   7th Feb 2019 
 1 
Two-year results of the randomised Diabetes Remission 
Clinical Trial (DiRECT) 
Professor Michael EJ Lean MD 1*, Wilma S Leslie PhD1, Alison C Barnes PGDip 2, Naomi Brosnahan 
PGDip1,6, George Thom MSc 1, Louise McCombie BSc1, Carl Peters MB3, Sviatlana Zhyzhneuskaya 
MD3, Ahmad Al-Mrabeh PhD3, Kieren G Hollingsworth PhD3, Angela M Rodrigues PhD4, Lucia 
Rehackova PhD4, Professor Ashley J Adamson2 PhD, Professor Falko F Sniehotta PhD4, Professor John 
C Mathers PhD 5, Hazel M Ross BSc 6, Yvonne McIlvenna MSc7, Paul Welsh PhD8, Sharon Kean9, 
Professor Ian Ford PhD9, Alex McConnachie PhD9, Claudia-Martina Messow PhD9 , Professor Naveed 
Sattar FMedSci8, Professor Roy Taylor MD3* 
 
1Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life 
Sciences, University of Glasgow, Glasgow, G31 2ER, UK 
2Human Nutrition Research Centre, Institute of Health & Society, Newcastle University, Newcastle 
upon Tyne NE2 4HH  
3Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, 
Campus for Ageing & Vitality, Newcastle upon Tyne NE4 5PL 
4Institute of Health & Society, Newcastle University, Newcastle upon Tyne NE2 4AX  
5Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle 
upon Tyne NE2 4HH 
6Counterweight Ltd, 85 Great Portland Street, First Floor, London, W1W 7LT 
7General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, 
Glasgow, G12 9LX 
Draft 7   7th Feb 2019 
 2 
 
9  
8Institute of Cardiovascular and Medical Science, University of Glasgow G12 8TA 
9Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, 
Glasgow G12 8QQ 
*Joint PIs 
 
Corresponding author:  Roy Taylor roy.taylor@newcastle.ac.uk 
Word count: Abstract 306.   Manuscript 3784   References 33 
Tables 2; Figures 3 
CONSORT FORM 
  
Draft 7   7th Feb 2019 
 3 
Research in Context 
 
Evidence before this study 
Before undertaking this study, the authors searched the published literature in PUBMED for 
evidence on remissions of type 2 diabetes, using all potential interventions.   For the present 
analysis, the authors reviewed new literature on remissions of type 2 diabetes through weight 
management, searching PUBMED since publication of the 12 month results of DiRECT (December 
2017) using search terms: clinical trial, remission, type 2 diabetes, weight loss.  The search revealed 
8 titles, of which only 3 indicated weight loss interventions.  Two of these were to DiRECT, and one 
to results from laparoscopic surgery, which was deemed not relevant.  
 
Added Value of this study 
The present study extends to 2 years evidence for durable remissions of type 2 diabetes following 
diet-induced weight loss.  Wider benefits relating to blood pressure, blood lipids, and well-being are 
demonstrated. It provides an increasingly confident answer to the top research question posed by 
people with type diabetes in the Diabetes UK/James Lind Alliance survey (published in The Lancet 
2017): ‘Can type 2 diabetes be cured or reversed?’ 
 
Implications of all the available evidence 
This study will provide added impetus to extend the early measures already announced to change 
existing NHS policy and practice for the routine management of type 2 diabetes.  The present data, 
and other relevant data on diabetes control, HbA1c and weight management all point towards the 
likelihood that intensive weight management has the potential to reduce or delay complications of 
diabetes and improve clinical outcomes. 
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ABSTRACT    
Background: DiRECT tested remission from Type 2 diabetes during a weight management 
programme.  At one year 46% of intervention participants were in remission and 25% achieved 
>15kg weight loss. The aim of this two-year analysis is to assess durability of outcomes.  
Methods: DiRECT is an open-label, cluster-randomised, controlled trial in primary care practices. 
Practices were randomly assigned (1.1) via a computer-generated list to an integrated structured 
weight management programme (intervention) or best-practice care by guidelines (control), with 
stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤ 5700). Allocation 
was concealed from the study statistician. Participants, carers and study research assistants were 
aware of allocation. We recruited individuals aged 20–65 years, with <6 years duration of type 2 
diabetes, body-mass index 27–45 kg/m2, and not receiving insulin between 25th July 2014 and 5th 
August 2016. The intervention comprised withdrawal of anti-diabetes and antihypertensive drugs, 
total diet replacement (825–853 kcal/day formula diet) for 12-20 weeks, stepped food 
reintroduction (2–8 weeks), and then structured support for weight loss maintenance.  Co-primary 
outcomes, analysed hierarchically, were weight loss >15 kg, and remission of diabetes, defined as 
HbA1c <6·5% (<48 mmol/mol) after withdrawal of anti-diabetes medications at baseline.  The 
intention to treat population comprised 149 participants per group.  The trial is registered with the 
ISRCTN registry, number 03267836 and follow up continues. 
Findings: At 24 months, 53/149 (35·6%) of those commencing the intervention and 5/149 (3·4%) in 
the control group (adjusted odds ratio 25·8, 95% CI 8·3,80·8; p<0·0001) had remission, and 11·4% 
(17/149 of intervention and 2·0% (3/149) of the control group (adjusted odds ratio 8·2 (2·2,30·0), 
p=0·002) had weight loss ≥15kg. Of those maintaining ≥10kg weight loss (45/272), 64% (29/45) 
achieved remission, and 24.2% (36/149) of the intervention group maintained ≥10kg weight loss 
(post hoc analysis). Adjusted mean differences between groups were in changes in body weight -5·4 
kg, (-6·9,-4·0), p<0·0001, in HbA1c  -4·8 mmol/mol, (-8·3,-1·4)(-2.59%), p=0·006 despite >50% fewer 
anti-diabetes agent use in intervention group, and SBP  -3·4 mmHg, (-6·7,-0·2), p=0·040.  Serum 
Draft 7   7th Feb 2019 
 5 
triglycerides decreased by 0·4 mmol/l (SD 1·2) (intervention) and by 0·2 mmol/l (SD 0·7) (control) 
(adjusted mean difference in log-transformed values -0·14 (-0·23, -0·04), p=0·006). Serious adverse 
events were similar at 12 months, but were fewer in intervention than control in the second year (9 
vs. 22). Quality of life improved more from baseline in the intervention than the control group, 
adjusted mean difference 4·6 (0·4,8·9, p=0·032). 
Interpretation:  This programme sustained remissions at 24 months for over a third of people with 
type 2 diabetes.  Weight loss of ≥10 kg provides remission for two thirds. 
Funding:  Diabetes UK.  
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Introduction 
Between one in 16 to 1 in 10 adults in the UK and US, respectively have type 2 diabetes 1,2, with 
much higher rates (up to 1 in 5) in other parts of the world3.  Diabetes complications are common 
and expensive to manage so associated healthcare costs are enormous despite the improvements 
offered through application of clinical guidelines. It is particularly devastating for the growing 
numbers of younger people affected, who tend to be more obese and lose more life-years through 
disabling and painful complications.4   
The extreme strength of association between excess weight gain in adult life and type 2 diabetes 
makes a causal relationship highly likely. The specific importance of intra-abdominal fat and large 
waist circumference has been long recognised, and the twin cycle mechanism, driven by a damaging 
but reversible accumulation of ectopic fat within the liver and pancreas in susceptible individuals, 
has now been consistently observed. 5-7 Several studies have now shown that weight loss of at least 
10-15 kg frequently normalises blood glucose in people with short-duration type 2 diabetes. 8-11 The 
Diabetes Remission Clinical Trial (DiRECT) demonstrated that almost half (46%) of a group with type 
2 diabetes up to 6 years duration could achieve remission at 12 months, by following a structured 
weight management programme 12 , and for 86% of those in the intervention group who achieved 
target weight loss of 15kg or more. These results have changed perceptions of a condition previously 
assumed to be permanent and demanding life-long drug treatment.   
The major current questions are whether remission can be durable and delivered at scale to reach 
the large numbers of patients, in primary care where they are usually managed, and by how much 
vascular complications of diabetes can be delayed or avoided.  Sufficient weight loss for remission, 
of over 10-15 kg, can be achieved in various ways, including bariatric surgery but also using a low-
calorie formula for total diet replacement.  The key issue now is how best to support long term 
maintenance of weight loss and remissions of diabetes. This is the greatest problem faced by 
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individuals, and still misunderstood and requiring specific research, as in the past formula diets were 
commonly regarded as effective only in the very short-term 13  
DiRECT was designed to test an integrated weight management programme delivered in primary 
care, with an initial period of effective weight loss, stepped food reintroduction with emphasis on 
energy balance, and then structured support for weight loss maintenance with provision for relapse 
management. We now report the clinical outcomes in the intervention and control groups at two 
years.  
Methods 
Study design and participants 
DiRECT is a two-year open-label, cluster-randomised controlled trial.  Ethics approval was granted by 
West 3 Ethics Committee in January, 2014, with approvals by the National Health Service (NHS) 
Health Boards in Scotland and Clinical Commissioning Groups in Tyneside. The trial is registered with 
the ISRCTN registry, number 03267836. 
The protocol, including details of recruitment methods, study conduct, and planned analyses, has 
been published elsewhere,14 as have the baseline characteristics of the groups.15 In brief, between 
25th July 2014 and 5th August 2016, we recruited individuals aged 20–65 years, diagnosed with type 2 
diabetes within the past 6 years, body-mass index 27–45 kg/m2, and not receiving insulin. All 
participants provided written informed consent for the two-year study. 
Randomisation and Masking 
Randomisation was conducted independently of the clinical research team, by the Robertson Centre 
for Biostatistics, University of Glasgow with the GP practice as unit of randomisation stratified by 
practice list size (>5700 or < 5700)  and study region (Scotland or Tyneside). Statisticians were 
blinded to treatment allocation for the primary analysis.  
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Procedures  
The intervention programme (Counterweight-Plus), delivered entirely within a routine primary care 
setting by a trained NHS dietitian or nurse (as available locally), comprised total diet replacement 
(825–853 kcal/day formula diet) for 3–5 months (flexible duration to allow for individual goals and 
circumstances), stepped food reintroduction (6–8 weeks), and then structured support for weight 
loss maintenance. For the maintenance phase up to 24 months, participants were offered monthly 
30 minute appointments with the dietitian or practice nurse, using tailored workbooks.  In the event 
of weight regain >2kg, participants were offered a ‘rescue plan’ of 2-4 weeks partial meal 
replacement, and if >4kg a total diet replacement and food reintroduction, with the offer of orlistat 
treatment.  Advice to increase daily physical activity was reinforced at each visit although no specific 
targets were set. Both anti-diabetic and antihypertensive drugs were withdrawn on day 1 of total 
diet replacement, with protocols for their reintroduction if necessary, according to clinical 
guidelines.  Antihypertensive drugs were withdrawn to avoid postural hypotension, as blood 
pressure generally decreases upon commencing a low energy diet.7  Participants in both groups 
continued to receive diabetes care under current guidelines and standards from the National 
Institute of Health and Care Excellence in England 16 and the Scottish Intercollegiate Guidelines 
Network in Scotland.17 These guidelines do not at present include any recommendations for 
therapeutic  trials of medication withdrawal, which are left to the discretion of doctors in the event 
of clinical improvement through lifestyle changes. All study appointments took place at the 
participants' own GP practices. 
 
Outcomes 
The co-primary outcomes were a reduction in weight of 15 kg or more, and remission of diabetes, 
defined as HbA1c less than 6·5% (<48 mmol/mol) following withdrawal of anti-diabetic agents at 
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baseline 18,19  . The only participant who received an agent after baseline withdrawal developed 
gestational diabetes and required insulin only during pregnancy. Secondary outcomes were quality 
of life, as measured by the EuroQol 5 Dimensions (EQ-5D-3L); serum lipids; and physical activity. 
Other pre-specified outcomes included programme acceptability, sleep quality, blood pressure, and 
serious adverse events collected from GP records, as detailed in the trial protocol.14  We additionally 
assessed changes in medications remission after >10kg weight loss as post hoc analyses.  Outcome 
data were collected at baseline and repeated at 12 and 24 months as planned.  All pre-specified 
outcomes are reported with the exception of exercise and sleep data which are not yet analysed.  
For participants who ceased to engage, and did not attend their 12 or 24-month trial appointments, 
data from GP records (within a window of plus or minus 100 days of the scheduled follow-up date) 
were used, if available, as pre-specified in the protocol.15 
Statistical analysis 
The planned primary analyses were done at the individual level, according to the intention-to-treat 
principle. The co-primary outcomes were analysed in a hierarchical manner, the weight loss 
outcome first, with no adjustment of the p-values for multiple comparisons. For participants who did 
not attend the 12 or 24 month study assessment, and for whom data could not be obtained from GP 
records, we made the assumption that the primary outcomes were not met. For the main analysis of 
secondary outcomes, no assumptions were made regarding missing data.  
Sample-size calculations indicated that recruitment of 280 participants would be required to achieve 
80% power. These calculations assumed diabetes remission in 22% of participants in the 
intervention group at one year (the effect size deemed potentially important, a priori) compared 
with an estimated 5% in the control group, enrolment of ten participants per practice (fixed), an 
intra-class correlation coefficient of 0·05 to account for cluster randomisation, and an estimated 
dropout rate of 25% within 12 months. 
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Outcomes were compared between groups with mixed-effects regression models, with adjustment 
for GP practice as a random effect. Logistic models were used for binary outcomes, and Gaussian 
models for continuous outcomes. If possible, models were adjusted for the minimisation variables 
(study centre and practice list size), age, sex, duration of diabetes and HbA1c at baseline. Models of 
continuous outcomes were also adjusted for the baseline measurement of the outcome. If models 
failed to converge, models with fewer adjustment variables were tried. For serum triglyceride, 
groups were compared with a linear regression model of log-transformed values, with adjustment 
for baseline log triglyceride. 
For continuous outcomes, model fit was assessed visually with normal probability plots. When 
substantial departure from a normal distribution was observed, groups were also compared with 
non-parametric Wilcoxon or Mann–Whitney tests, using both the 24-month outcome value and the 
change from baseline. For binary outcomes, when the number of cases or non-cases was zero in one 
of the randomised groups and the regression model would not converge, we compared groups with 
Fisher's exact test. 
Statistical analyses were done with R for Windows, version 3.2.4.  
Role of the funding source 
The study funders had no role in study design, data collection, data analysis, interpretation, or 
writing of the report. All authors had full access to all the study data and the corresponding author 
had final responsibility for the decision to submit for publication. 
Results 
Between 25th July 2014 and 5th August 2016, we recruited 306 individuals from 49 intervention 
(n=23) and control (n=26) practices, and the intention-to-treat population comprised 149 
participants per group (Figure 1). Baseline characteristics were similar between groups.15 
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A total of 116/149 (77·9%) participants in the intervention and 141/149 (94·6%) in the control group 
attended the 24 month study assessment, thus overall 41/298 (13·8%) randomised participants did 
not attend at 24 months. The baseline characteristics of those who attended this visit compared 
with those who did not are shown in Table S1. Additional data for weight and HbA1c were obtained 
from GP records where available, such that data at 24 months for body weight and for HbA1c were 
available for 272 (91·3%) participants (n=129 intervention and n=143 control).  For the intention-to-
treat analysis, the remaining 26 participants with no data at 24 months, who did not attend the 12 
or 24 month study assessment, and for whom GP records were not available because they had 
moved residence or practice and could not be traced, were assumed not to have met either primary 
outcome (Figure 1). 
The intervention group participants attended an average of 7·7 appointments of the possible 12 
visits at monthly intervals during the second year, and those who attended the two-year follow-up 
visit attended 9·6 out of the maximum of 12 visits. 
 
At 24 months, weight loss of 15 kg or more was observed in 17/129 (13·2%) intervention group 
participants (17/149, 11·4% of those commencing the intervention), and by 3/149 participants in the 
control group (adjusted odds ratio 7·49, 95% CI 2·05-27·32, p=0·0023, missing values imputed; Figure 
2A). In the intervention group 24.2% (36/149) maintained ≥10kg weight loss at 24 months (post hoc 
analysis). Absolute weight at each time point is shown in Table 1.  
At 24 months, without imputing missing data and assuming no remission for those without data, 
diabetes was in remission in 53/129 (41·1%) participants in the intervention group (35·6% of 149 
commencing the intervention) and 5/149 (3·4%) in the control group (adjusted odds ratio for 
imputed outcome 25·82, 95% confidence interval (8·25, 80·84); p<0·0001).   (Figure 2B). 
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For the entire study population, remissions at 24 months were achieved by 8/154 (5.2%) participants 
who lost less than 5 kg, 21/73 (28·8%) who maintained 5–10 kg loss, 15/25 (60·0%) who maintained 
10–15 kg loss, 29/45 (64·4%) who maintained ≥10kg loss, and 14/20 (70·0%) of participants who lost 
15 kg or more (Figure 2C).  Four participants (out of 50 with weight gain (8·0%)) were in remission at 
both 12 and 24 months despite small weight gains (0-2kg) at 24 months. These individuals all had 
baseline Hba1c between 6.5% (47.5mmol/mol) and 6.63% (49.0 mmol/mol). Of those on anti-
diabetic medication, 22/119 (18·5%) in the control group and 0/51 in the intervention group had 
HbA1c<48 mmol/mol at 24 months. In the control group, 4/119 (3·4%) had HbA1c<42 mmol/mol at 
24 months. Post-hoc analyses were conducted on the change in weight by achieved remission at 
each time point (Figure S1) and the baseline characteristics of those attending the 24 months visit 
compared with those who did not (Table S1).  
Between baseline and 24 months, mean body weight fell by 7·6kg (SD 6·5) in the intervention group 
and by 2·3 kg (SD 5·2) in the control group (adjusted difference in weight change between groups at 
24 months of -5·43 kg, 95% CI -6·87 to -3·99; p<0·0001; Table 1).  
Between 12 and 24 months, mean body weight increased by 2·6 kg (SD 5·0) in the intervention 
group and decreased by 1·3 kg (SD 4·2) in the control group (adjusted difference in weight change 
between groups of 3·34 kg, 95% CI 2·18 to 4·50; p<0·0001). In the intervention group, those 
maintaining remission between 12 and 24 months (n=48), after having lost on average 15·51 kg (6·6) 
during year 1, regained on average 4·25 kg, SD 3·68. In those who relapsed after 12 months (n=15) 
weight regain was greater (7·09 kg (SD 5·42), t-test p=0·073), after having lost an average of 11·98 kg 
(SD 7·7). The group not in remission at 12 months (n=62 with weight data at both 12 and 24 months) 
had an average weight gain of 0.26 kg (SD 4.7) after having lost 5·81 (SD 6·4) at 12 months. Over the 
24 months from baseline, those who maintained remission lost an average of 10·4 kg (SD 6·8), those 
who were in remission at 12 months but relapsed at 24 months lost 3·7 kg (SD 5·9) and those who 
did not achieve remission at 12 or 24 months lost 3·2 (5·2) kg (Figure S1). Out of 143 intervention 
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arm participants who have data during treatment phases, about half required relapse management 
with brief total diet replacement and the offer of orlistat during the two years: 71/143 (49·7%) had 
not had any ‘rescue plan’, 49/143 (34·3%) had one, 15/143 (10·5%) had two and 8/143 (5·6%) had 
three or more rescue plan phases.  The numbers of intervention arm participants receiving orlistat at 
12 and 24 months were 0 and 3 respectively. As the mean baseline weight was close to 100kg, 
similar patterns were recorded for BMI and for weight change expressed as a percentage of baseline 
weight. 
In the control group, mean HbA1c remained similar between baseline (58·2 mmol/mol,SD 11·5; 
7.48%) and 24 months (58·6, SD 14·4; 7.51%), with 115/149 (77·2%) receiving anti-diabetes 
medications at baseline, increasing to 120/143 (83·9%) at 24 months. In the intervention group, 
mean HbA1c fell between baseline (60·4, SD 13·7; (7.68%)) and 24 months (54·4, SD 15·9), adjusted 
mean difference -4·82mmol/mol, (-8·28, -1·36), p=0·0063, with 111/149 (74·5%) receiving anti-
diabetes medications at baseline and 51/129 (39·5%) at 24 months.   
Of those on anti-diabetic medication, 22/119 (18·5%) in the control group and 0/51 in the 
intervention group had HbA1c<48 mmol/mol at 24 months, and 4/119 (3·4%) in the control group 
had HbA1c<42 mmol/mol at 24 months. 
Mean systolic blood pressure at 24 months decreased by 1·4 mmHg (SD 13·4) in the control group 
and by 4·3 mmHg (SD 18·7) in the intervention group (adjusted mean difference -3·43, (-6·70, -0·16), 
p=0·039), with 86/143 (60·1%) in the control group but only 61/129 (47·3%) in the intervention 
group receiving antihypertensive medication at 24 months (adjusted odds ratio 0·31, (0·14, 0·71), 
p=0·0058)(Table 1). 
Serum triglycerides at 24 months decreased below baseline values by 0·2 mmol/l (SD 0·7) in the 
control group and by 0·4 mmol/l (SD 1·2) in the intervention group (adjusted mean difference in log-
transformed values -0·14 (-0·23, -0·04), p=0·0055). 
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Total serious adverse events reported for the first 24 months of DiRECT were 15 in the intervention 
and 25 in the control group, in 11 and 19 participants respectively.  While there had been no 
significant difference at 12 months, in the second year of DiRECT, six participants in the intervention 
group and 16 in the control group suffered nine and 22 serious adverse events respectively. None 
led to withdrawal from the study.  The serious adverse events (Table 2) included several vascular 
events in the control arm (two cerebral vascular accidents, one toe amputation, one aortic aneurysm 
rupture, and one sudden death), compared with one non-fatal MI in the intervention group in a 
person who had not attended for review. Two other serious adverse events, both in one participant 
during year one (cholelithiasis, abdominal pain), were deemed potentially related to the 
intervention.  
Quality of life assessed by visual analogue score at 24 months improved more in the intervention 
group (change from baseline 10·0 (0·0, 20·0) than in controls 2·5 (-5·0, 9·0); p=0·032)).  The absolute 
scores are shown in Table 1.  
Post hoc analysis showed that in the whole study population, likelihood of remission at 24 months 
(n=58/298, 19.5%) was higher for male sex (adjusted odds ratio for female vs. male 0·44 (0·22, 0·88), 
p=0·020), and increased with age (adjusted odds ratio 1·08 (1·03, 1·13) per year, p=0·0020), , with 
weight loss from baseline (adjusted odds ratio 0·83 (0·77, 0·90) per kg, p<0·0001), and with weight-
change from 12 to 24 months (adjusted odds ratio per kg gained 1.11 (1·03, 1·21), p=0·010).  
Likelihood of remission at 24 months was not influenced by baseline BMI (adjusted odds ratio per 
kg/m2 0·99 (0·92, 1·06), p=0·77) or duration of diabetes within the 6-year range included (adjusted 
odds ratio per year 0·92 (0·76, 1·11), p=0·39). Where this could be assessed, the effects did not differ 
significantly between intervention and control group (p for interaction: sex p=0·31, weight change 
from 12 to 24 months p=0·47, duration of diabetes within the 6 year range studied p=0·11). All 
models were adjusted for treatment, practice list size, centre and a random effect for practice. 
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Discussion 
The two-year results of DiRECT demonstrate continuing remission of type 2 diabetes is possible. The 
present data demonstrate that diabetes is reversible to a non-diabetic state over 24 months for 36% 
of the whole Intervention group and for 70% of those who maintain a weight loss of over 15kg. The 
data extend the 1st year data of DiRECT in showing that achieving and maintaining weight loss is the 
dominant factor behind remission of type diabetes. Participants reverting to diabetes between 12 
and 24 months regained more weight than those maintaining remission. The co-primary outcome 
of >15kg weight loss was maintained by 11.4% (17/149) by intention to treat analysis, down from 
24% (36/149) at 1 year. Blood pressure, lipids and quality of life improved with the intervention. 
There were less serious adverse events in the intervention group in the second year. The overall 
diabetes-related cardiometabolic risk profile improved, with reduced lipids and fewer participants 
requiring antihypertensive medications to control blood pressure than in the control group.   
To our knowledge, DiRECT is the first study designed to test whether, and for how long, dietary 
weight loss can generate remission of type 2 diabetes. The programme used differs from many 
weight management treatments in its structured design, with a three-phase integrated structure, 
focussing from the outset on the need for long-term maintenance of weight loss. The importance of 
a formalised rescue plan is underscored by observation that almost half of the Intervention group 
required this additional intervention. Of the 129 participants with data on medication, 53 were in 
remission, 51 were on anti-diabetic medication and 25 had not achieved remission but had not been 
commenced on medication. Weight regain was less than in many published studies13 but remains a 
challenge. The observed weight regain and remission rates compare favourably with Look AHEAD20, 
which delivered an intensively supported programme in specialist US diabetes centres, combining 
considerable increases in physical activity and dietary programmes. Losing over 10kg in Look Ahead 
was associated with reduced cardiovascular events in a post hoc analysis. Remission of type 2 
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diabetes was not the primary outcome in Look Ahead, but was observed in 9·2% at 2 years, with 
average weight loss of a little under 6kg.21  The DiRECT intervention has similarities with Look Ahead, 
but was designed specifically for achieving remissions, with a view to delivery at scale for the very 
large numbers of people with type 2 diabetes, therefore in a routine primary care setting. The 
results will help to overcome reluctance to offer weight management in primary care, whether 
through unfamiliarity with practical weight management or a belief that weight regain is inevitable 
and usually complete. Weight changes at 24 months in DiRECT are comparable to those reported 
using the same programme in a prospective audit of its routine use in other primary care and 
community settings, which found similar results for people with and without diabetes.22 The 
resources required for a programme based on the DiRECT intervention are not complicated or 
expensive, nor the training of routine staff burdensome. The 12-month intervention cost is under 
half of the average annual UK healthcare cost of a person with type 2 diabetes.23 These 
considerations, and the fact that DiRECT included a high proportion of participants from more 
socially deprived backgrounds 15 (unlike many other programs), all imply that the intervention should 
be widely transferable within routine healthcare. Acceptability of the intervention is supported by a 
sustained modest, statistically significant improvement in quality of life.   
Bariatric surgery has dominated discussions of type 2 diabetes remission as an effective way of 
producing major weight loss and diabetes remissions.9-11 However, it is expensive and incurs risks of 
long-term problems, such as post-prandial hypoglycaemia, hypovolaemic dumping syndrome and 
micronutrient deficiencies that restrict acceptability.24,25 In addition, many people do not wish to 
undergo surgery.  The results of DiRECT and some previous studies26 challenge the view that the very 
large weight losses targeted by bariatric surgery are essential or optimal for sustained remission of 
type 2 diabetes. DiRECT provides the best evidence from a real-life trial of a non-surgical approach, 
but research into prevention of weight regain remains underdeveloped, and improved methods will 
be needed to match the long-term weight loss maintenance after surgery. Accumulated evidence 
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points to duration of diabetes with earlier age of onset and persistent elevation of HbA1c as the 
main drivers of the disabling and costly clinical complications of type 2 diabetes, in particular the 
vascular consequences of associated hypertension and dyslipidaemia.27 DiRECT was not powered to 
assess ‘hard’ clinical outcomes, but seeing fewer serious adverse events in the second year of weight 
management is reassuring, given the past anxiety over safety of older formula diets. The present 
observations on these improved cardiovascular risk factors are consistent with other evidence for 
clinical benefits from intentional weight loss for people with type 2 diabetes28.The potential 
advantages of remission are enormous but no long-term outcome data yet exist, other than after 
bariatric surgery. 9  
The present results suggest that type 2 diabetes is a clinical consequence of accumulation of excess 
weight, in ectopic sites by susceptible individuals, 7 even with a relatively low body mass index. The 
observation of changes in liver and pancreas fat which accompany weight loss with biochemical 
improvements in type 2 diabetes are consistent with this.29,7 It appears that failure to tackle that 
underlying process of fat accumulation allows diabetes to progress. Effective long-term weight 
management with a resetting of long-term energy consumption is clearly essential, but other factors 
contribute and there remain unanswered questions and debates about dietary approaches, and the 
optimal ratio of macronutrients. A recent study of people with type 2 diabetes has demonstrated 
substantial weight loss, reduced glycaemia and decreased medications with a very low carbohydrate 
diet, although this was not randomised.30  However, meta-analyses of the controlled trial evidence 
show no important differences between high and low carbohydrate diets for weight control or 
HbA1c.31 Low intensity support and follow-up to establish longer term outcomes in DiRECT are 
currently funded to continue for all participants to a total of 3 years from baseline, and participants 
have consented to 5 years of follow up. While weight maintenance in DiRECT is better than in most 
previous studies, further research to optimise weight loss maintenance is essential. This could 
potentially incorporate other dietary methods, and medications if individually required, such as GLP-
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1 agonists32 or non-pharmaceutical agents like inulin propionate ester 33 where appropriate and 
necessary for those who fail to maintain remissions long-term. The present results make a strong 
case that intensive weight management should be included as a first-line option in routine care for 
people with type 2 diabetes, to seek early remission from a potentially devastating progressive 
disease.18   
Some limitations and potential for bias are inevitable in research conducted in real-life settings. 
Although statisticians were blinded for the primary analysis, participants and clinicians in DiRECT 
were aware of their planned allocation to the control or intervention group, as the unit of 
randomisation was the primary care centre, to reduce contamination between groups. Following 
publication of the first-year results of DiRECT (December 201712) there was considerable media 
coverage which may have tended to attenuate the difference between the randomised groups. A 
proportion of the control group took personal action to lose weight (9 participants in the control 
group lost >10 kg during the second year compared to 2 during the first year). Increased use of SGLT-
2 inhibitors may also have contributed to the weight change in controls. At 12 months no control 
participants had achieved the co-primary outcome of weight loss greater than 15kg, but at 24 
months it was reached by 3 (3/149, 2·0%), and there was a significant difference between the weight 
loss in the control group and weight gain in the intervention group. Despite this the differences in 
remission and weight loss between groups were still highly significant and clinically important at 2 
years. Weight regain in the intervention group contributed to limit the effect size. The racial and 
ethnic characteristics, while typical of UK type 2 diabetes populations, do not allow for unqualified 
extrapolation to other groups, such as South Asians, who tend to develop diabetes with less weight 
gain (and may therefore need less weight loss to undergo remission). The conclusions reported here 
apply to people with type 2 diabetes diagnosed within the previous 6 years, and existing evidence 
has shown that remission, though still possible, is less likely after longer durations of disease.7-9 As 
medication withdrawal is not part of standard guidelines, it has to be considered that some control 
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participants might have been able to sustain HbA1c below the cut off for remission if their anti-
diabetic agents had been withdrawn. Of those in the Intervention group who did not achieve 
remission, anti-diabetic agents required to be re-started as per protocol in 39.5%. The strengths of 
the study include a well-defined intervention and a robust cluster-randomised study design, 
managed by a well-established clinical trials unit. The sample had characteristics very similar to the 
general population of people with type 2 diabetes, so the results are likely to be widely 
generalisable.15 The study was well powered for the co-primary outcomes of remission and weight 
change at the primary analysis point at 1 year and we now observe clinically meaningful outcomes at 
2 years. Relating to this, the overall loss to follow up of 13·8% (41/298) over 2 years is modest for a 
weight loss study in real-life conditions.14  
In conclusion, the 2-year results of DiRECT confirm that type 2 diabetes is potentially reversible by 
weight loss in most cases.  A structured primary care weight management programme within 6 years 
of diagnosis can sustain remission to a non-diabetic state, off anti-diabetes drugs, for over a third of 
people with type 2 diabetes and over two thirds of those who lost more than 10kg at 24 months. 
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Legends to Figures 
 
Figure 1: Trial profile 
 
Figure 2: Primary outcomes and remission of diabetes in relation to weight loss at 12 and at 24 
months. Regression models adjusting for practice list size, study centre and a random effect for 
practice.  
A: First co-primary outcome, achievement of ≥15kg weight loss, by randomised group. B: Second co-
primary outcome, remission of diabetes (HbA1c <48mmol/mol, off anti-diabetic medication for 2 
months), by randomised group.  
C: Remission of diabetes, in relation to weight loss achieved (both randomised groups combined). 
 
Figure 3: Changes in weight of participants who remained in the trial and those who dropped out 
during each phase of the intervention.  
Error bars represent 95% CI 
 
 
Figure S1: Median weight change shown by remission status. Error bars represent interquartile 
range.  
 
ITT=intention-to-treat. *Four intervention practices and two control practices were not required for recruitment, which 
was done sequentially by practice to allow for training of practice staff. Therefore, 49 practices were asked to recruit 
participants. †Baseline glycated haemoglobin less than 6·5% (48mmol/mol). 
 
Figure 1: Trial Profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1510 individuals screened for eligibility  
117 excluded at screening  
306 individuals consented and enrolled  
423 individuals agreed to participate  
157 individuals assigned to the intervention group 
86 in Scotland 
71 in Tyneside 
149 individuals assigned to the control group   
125 in Scotland  
24 in Tyneside 
55 general practices recruited and randomised  
27 assigned to the intervention group 
28 assigned to the control group 
23 practices assigned to the intervention group 
15 in Scotland  
8 Tyneside  
26 practices assigned to the control group 
19 in Scotland  
7 in Tyneside 
49 practices used for recruitment of participants*  
1087 not enrolled 
246 declined 
841 did not respond 
7 randomised in error (already in 
remission at baseline) † 
150 commenced Intervention 
149 included in ITT analysis @ 12 months 
(128 attended; data taken from GP records for 20) 
149 included in ITT analysis @12 months 
(147 attended; data taken from GP records for 1) 
1 withdrew consent for data use  
149 included in ITT analysis @ 24 months 
(116 attended; data taken from GP records for 13) 
149 included in ITT analysis @ 24 months 
(140 attended; data taken from GP records for 3) 
32 withdrew from intervention 
16 withdrew from intervention 
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Figure S1   Median weight change shown by remission status. Error bars 
represent interquartile range.  
  
 Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
Age (years) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
54.4 (7.6) 
55.1 
(49.2, 60.9) 
[30.8, 65.9] 
41  
49.2 (8.8) 
48.9 
(43.8, 54.3) 
[30.8, 65.4] 
257  
55.2 (7.0) 
55.6 
(50.6, 61.1) 
[32.4, 65.9] 
p<0.0001 W 
Sex 
 
Number 
N (%) Male 
N (%) Female 
298  
176 (59.1%) 
122 (40.9%) 
41  
21 (51.2%) 
20 (48.8%) 
257  
155 (60.3%) 
102 (39.7%) 
p=0.31 F 
Years since diabetes diagnosis 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
3.0 (1.7) 
3.0 
(1.5, 4.5) 
[0.0, 6.0] 
41  
2.1 (1.8) 
1.6 
(0.6, 3.5) 
[0.1, 5.8] 
257 
3.1 (1.7) 
3.1 
(1.7, 4.6) 
[0.0, 6.0] 
p=0.0001 W 
HbA1c (mmol/mol), from GP records 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
61.6 (13.9) 
58.0 
(51.0, 68.0) 
[43.0, 107.0] 
41  
66.1 (16.8) 
62.0 
(52.0, 79.0) 
[44.0, 105.0] 
257 
60.9 (13.3) 
57.0 
(51.0, 67.0) 
[43.0, 107.0] 
p=0.075 W 
HbA1c (%), from GP records 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
7.79 (1.27) 
7.46 
(6.82, 8.37) 
[6.09, 11.94] 
41  
8.20 (1.54) 
7.82 
(6.91, 9.38) 
[6.18, 11.76] 
257  
7.72 (1.21) 
7.37 
(6.82, 8.28) 
[6.09, 11.94] 
p=0.075 W 
Weight (kg) 
Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
99.9 (16.4) 
99.0 
(87.7, 109.5) 
[67.0, 149.1] 
41 (0) 
101.7 (17.8) 
102.0 
(88.9, 109.7) 
[74.3, 146.7] 
257 (0) 
99.6 (16.2) 
98.7 
(87.6, 109.0) 
[67.0, 149.1] 
p=0.52 W 
BMI (kg/m2) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
34.6 (4.4) 
34.1 
(31.1, 37.5) 
[27.3, 44.9] 
41 (0) 
35.4 (4.4) 
35.9 
(32.9, 38.4) 
[27.8, 44.9] 
257 (0) 
34.5 (4.4) 
34.0 
(30.8, 37.4) 
[27.3, 44.9] 
p=0.18 W 
SBP (mmHg) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
134.9 (16.9) 
134.0 
(122.1, 144.0) 
[100.0, 194.5] 
41 (0) 
129.8 (17.9) 
128.0 
(119.0, 138.0) 
[100.0, 171.5] 
257 (0) 
135.8 (16.6) 
135.0 
(123.0, 145.0) 
[100.0, 194.5] 
p=0.027 W 
History of Heart Failure 
 
Number 
N (%) Yes 
N (%) No 
298  
2 (0.7%) 
296 (99.3%) 
41  
2 (4.9%) 
39 (95.1%) 
257  
0 (0.0%) 
257 (100.0%) 
p=0.019 F 
Albumin/Creatinine Ratio (mg/mmol) (values <0.5 imputed as 0.25) 
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
292 (6) 
2.16 (6.89) 
0.25 
(0.25, 1.38) 
[0.25, 89.97] 
37 (4) 
5.40 (15.37) 
0.84 
(0.25, 3.44) 
[0.25, 89.97] 
255 (2) 
1.69 (4.38) 
0.25 
(0.25, 1.20) 
[0.25, 46.85] 
p=0.005 W 
Microalbuminuria, defined as ACR≥3.5 (female) or ACR≥2.5 (male) 
 
Nobs (Nmiss) 
N (%) No 
N (%) Yes 
292 (6) 
253 (86.6%) 
39 (13.4%) 
37 (4) 
26 (70.3%) 
11 (29.7%) 
255 (2) 
227 (89.0%) 
28 (11.0%) 
p=0.004 F 
Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
C-rP (mg/l) 
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
291 (7) 
3.33 (3.64) 
2.21 
(1.12, 4.32) 
[0.10, 32.09] 
37 (4) 
4.45 (4.25) 
3.29 
(1.95, 5.26) 
[0.51, 24.70] 
254 (3) 
3.17 (3.52) 
2.04 
(1.10, 3.86) 
[0.10, 32.09] 
p=0.003 W 
HDL Cholesterol (mmol/l) 
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
291 (7) 
1.12 (0.28) 
1.09 
(0.92, 1.28) 
[0.35, 2.61] 
37 (4) 
1.02 (0.26) 
0.98 
(0.88, 1.15) 
[0.35, 1.72] 
254 (3) 
1.13 (0.28) 
1.11 
(0.94, 1.30) 
[0.40, 2.61] 
p=0.015 W 
 
 
 
  
Table S2 Summary of weight change from baseline by use of antidiabetic medications 
   Weight change at 
   12 Months 24 Months 
All participants   -5.3 (7.6), n=285 -4.8 (6.4), n=272 
On anti-diabetic medication at   
Baseline 12 Months 24 Months   
No No No -7.9 (7.1), n=45 -5.3 (5.2), n=44 
No No Yes -2.8 (5.3), n=7 -2.8 (4.3), n=8 
No Yes No -5.3 (-), n=1 -3.7 (-), n=1 
No Yes Yes -4.2 (5.6), n=7 -6.0 (3.9), n=7 
Yes No No -13.4 (8.3), n=52 -9.9 (7.5), n=53 
Yes No Yes -5.3 (6.7), n=14 -4.4 (2.7), n=16 
Yes Yes No 1.9 (5.2), n=2 3.3 (7.1), n=2 
Yes Yes Yes -1.8 (5.0), n=140 -3.0 (5.7), n=140 
 
  
Table S3 Summary of weight change from baseline by use of anti-diabetic medications 
   Weight change at 
   12 Months 24 Months 
All   -5.3 (7.6), n=285 -4.8 (6.4), n=272 
On anti-diabetic medication at   
Baseline 12 Months 24 Months   
Intervention group 
No No No -11.7 (6.8), n=26 -7.8 (5.1), n=26 
No No Yes -3.7 (7.7), n=2 -4.2 (6.5), n=3 
No Yes No - (-), n=0 - (-), n=0 
No Yes Yes - (-), n=0 - (-), n=0 
Yes No No -13.7 (8.1), n=51 -10.1 (7.5), n=52 
Yes No Yes -5.3 (6.7), n=14 -4.4 (2.7), n=16 
Yes Yes No - (-), n=0 - (-), n=0 
Yes Yes Yes -6.4 (6.6), n=32 -5.5 (5.6), n=32 
Control group 
No No No -2.7 (3.2), n=19 -1.6 (2.4), n=18 
No No Yes -2.5 (5.2), n=5 -2.0 (2.8), n=5 
No Yes No -5.3 (-), n=1 -3.7 (-), n=1 
No Yes Yes -4.2 (5.6), n=7 -6.0 (3.9), n=7 
Yes No No -0.4 (-), n=1 -2.1 (-), n=1 
Yes No Yes - (-), n=0 - (-), n=0 
Yes Yes No 1.9 (5.2), n=2 3.3 (7.1), n=2 
Yes Yes Yes -0.5 (3.4), n=108 -2.3 (5.6), n=108 
 
 
 
 
